H. Tunstall-pedoe, D. Vanuzzo, M. Hobbs, M. Mahonen, Z. Cepaitis et al., Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations, The Lancet, vol.355, issue.9205, pp.355688-700, 2000.
DOI : 10.1016/S0140-6736(99)11181-4

L. Palmieri, K. Bennett, S. Giampaoli, and S. Capewell, Explaining the Decrease in Coronary Heart Disease Mortality in Italy Between 1980 and 2000, American Journal of Public Health, vol.100, issue.4, pp.684-692, 1980.
DOI : 10.2105/AJPH.2008.147173

L. Bjorck, A. Rosengren, K. Bennett, G. Lappas, and S. Capewell, Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002, European Heart Journal, vol.30, issue.9, pp.1046-1056, 1986.
DOI : 10.1093/eurheartj/ehn554

S. Hardoon, P. Whincup, L. Lennon, S. Wannamethee, S. Capewell et al., How Much of the Recent Decline in the Incidence of Myocardial Infarction in British Men Can Be Explained by Changes in Cardiovascular Risk Factors?: Evidence From a Prospective Population-Based Study, Circulation, vol.117, issue.5, pp.598-604, 2008.
DOI : 10.1161/CIRCULATIONAHA.107.705947

A. Grahami, . Borch-johnsenk, . Boyseng, . Burellg, . Cifkovar et al., European guidelines on cardiovascular disease prevention in clinical practice: Executive summary, Atherosclerosis, vol.194, issue.1, pp.282375-2414, 2007.
DOI : 10.1016/j.atherosclerosis.2007.08.024

R. Conroy, K. Pyorala, A. Fitzgerald, S. Sans, A. Menotti et al., Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project, European Heart Journal, vol.24, issue.11, pp.24987-1003, 2003.
DOI : 10.1016/S0195-668X(03)00114-3

Z. Reiner, A. Catapano, D. Backer, G. Graham, I. Taskinen et al., /EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Eur Heart J, issue.14, pp.321769-1818, 2011.

D. Agostino, R. Sr, R. Vasan, M. Pencina, P. Wolf et al., General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study, Circulation, vol.117, issue.6, pp.743-753, 2008.
DOI : 10.1161/CIRCULATIONAHA.107.699579

J. Danesh, J. Wheeler, G. Hirschfield, S. Eda, G. Eiriksdottir et al., C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease, pp.3501387-1397

J. Danesh, P. Whincup, M. Walker, L. Lennon, A. Thomson et al., Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses, BMJ, vol.321, issue.7255, pp.321199-204, 2000.
DOI : 10.1136/bmj.321.7255.199

S. Kaptoge, D. Angelantonio, E. Pennells, L. Wood, A. White et al., Creactive protein, fibrinogen, and cardiovascular disease prediction, N Engl J Med, vol.2012, issue.14, pp.3671310-1320

J. Casas, T. Shah, A. Hingorani, J. Danesh, and M. Pepys, C-reactive protein and coronary heart disease: a critical review, Journal of Internal Medicine, vol.7, issue.4, pp.295-314, 2008.
DOI : 10.1111/j.1365-2796.2008.02015.x

P. Ridker, E. Danielson, F. Fonseca, J. Genest, A. Gotto et al., Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N Engl J Med, issue.21, pp.3592195-2207, 2008.

P. Ridker, N. Rifai, M. Clearfield, J. Downs, S. Weis et al., Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events, N Engl J Med, issue.26, pp.3441959-1965, 2001.

F. Rodriguez-artalejo, E. Guallar, C. Borghi, J. Dallongeville, D. Backer et al., Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA), BMC Public Health, vol.336, issue.1, p.382, 2010.
DOI : 10.1136/bmj.39609.449676.25
URL : https://hal.archives-ouvertes.fr/inserm-00622725

J. Banegas, E. Lopez-garcia, J. Dallongeville, E. Guallar, J. Halcox et al., Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study, European Heart Journal, vol.32, issue.17, pp.322143-2152, 2011.
DOI : 10.1093/eurheartj/ehr080

J. Dallongeville, J. Banegas, F. Tubach, E. Guallar, C. Borghi et al., Survey of physicians??? practices in the control of cardiovascular risk factors: the EURIKA study, European Journal of Preventive Cardiology, vol.106, issue.25, pp.541-550, 2011.
DOI : 10.1097/HJR.0b013e3283383f30

J. Huffman and M. Pollack, Predicting Panic Disorder Among Patients With Chest Pain: An Analysis of the Literature, Psychosomatics, vol.44, issue.3, pp.222-236, 2003.
DOI : 10.1176/appi.psy.44.3.222

W. Friedewald, R. Levy, and D. Fredrickson, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin Chem, vol.18, issue.6, pp.499-502, 1972.

K. Alberti, R. Eckel, S. Grundy, P. Zimmet, J. Cleeman et al., Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity, Circulation, vol.120, issue.16, pp.1640-1645, 2009.
DOI : 10.1161/CIRCULATIONAHA.109.192644

P. Ridker, J. Buring, N. Rifai, and N. Cook, Development and Validation of Improved Algorithms for the Assessment of Global Cardiovascular Risk in Women, JAMA, vol.297, issue.6, pp.611-619, 2007.
DOI : 10.1001/jama.297.6.611

P. Ridker and R. Glynn, JUPITER, rosuvastatin, and the European Medicines Agency, The Lancet, vol.375, issue.9731, p.2071
DOI : 10.1016/S0140-6736(10)60760-X

L. , D. Liu, K. Tian, L. Greenland, and P. , Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease, Ann Intern Med, vol.145, issue.1, pp.35-42, 2006.

R. Morrissey, G. Diamond, and S. Kaul, The JUPITER trial: myth or reality? Curr Atheroscler Rep, pp.413-421, 2011.

N. Sattar, A. Mcconnachie, O. Reilly, D. Upton, M. Greer et al., Inverse Association Between Birth Weight and C-Reactive Protein Concentrations in the MIDSPAN Family Study, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.24, issue.3, pp.583-587, 2004.
DOI : 10.1161/01.ATV.0000118277.41584.63

S. Lakoski, M. Cushman, W. Palmas, R. Blumenthal, D. Agostino et al., The Relationship Between Blood Pressure and C-Reactive Protein in the Multi-Ethnic Study of Atherosclerosis (MESA), Journal of the American College of Cardiology, vol.46, issue.10, pp.461869-1874, 2005.
DOI : 10.1016/j.jacc.2005.07.050

N. Timpson, D. Lawlor, R. Harbord, T. Gaunt, I. Day et al., H a t t e r s l e yA T ,E b r a h i mS ,L o w eG D ,R u m l e yA ,D a v e yS m i t hG :Creactive protein and its role in metabolic syndrome: mendelian randomisation study, Lancet, issue.9501, pp.3661954-1959, 2005.

T. Schindler, J. Cardenas, J. Prior, A. Facta, M. Kreissl et al., Relationship Between Increasing Body Weight, Insulin Resistance, Inflammation, Adipocytokine Leptin, and Coronary Circulatory Function, Journal of the American College of Cardiology, vol.47, issue.6, pp.471188-1195, 2006.
DOI : 10.1016/j.jacc.2005.10.062
URL : http://doi.org/10.1016/j.jacc.2005.10.062

M. Woodward, A. Rumley, P. Welsh, S. Macmahon, and G. Lowe, A comparison of the associations between seven hemostatic or inflammatory variables and coronary heart disease, Journal of Thrombosis and Haemostasis, vol.165, issue.9, pp.1795-1800, 2007.
DOI : 10.1111/j.1538-7836.2007.02677.x

S. Boekholdt, M. Meuwese, N. Day, R. Luben, A. Welch et al., Plasma concentrations of ascorbic acid and C-reactive protein, and risk of future coronary artery disease, in apparently healthy men and women: the EPIC-Norfolk prospective population study, Br J Nutr, issue.3, pp.96516-522, 2006.

D. Smith, G. Timpson, N. Lawlor, and D. , C-reactive protein and cardiovascular disease risk: still an unknown quantity? Ann Intern Med, pp.70-72, 2006.

W. Koenig, H. Lowel, J. Baumert, and C. Meisinger, C-Reactive Protein Modulates Risk Prediction Based on the Framingham Score: Implications for Future Risk Assessment: Results From a Large Cohort Study in Southern Germany, Circulation, vol.109, issue.11, pp.1349-1353, 2004.
DOI : 10.1161/01.CIR.0000120707.98922.E3

M. Albert, R. Glynn, J. Buring, and P. Ridker, C-Reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study), The American Journal of Cardiology, vol.93, issue.10, pp.931238-1242, 2004.
DOI : 10.1016/j.amjcard.2004.01.067

S. Anand, F. Razak, Q. Yi, B. Davis, R. Jacobs et al., C-Reactive Protein as a Screening Test for Cardiovascular Risk in a Multiethnic Population, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.24, issue.8, pp.241509-1515, 2004.
DOI : 10.1161/01.ATV.0000135845.95890.4e

A. Khera, D. Mcguire, S. Murphy, H. Stanek, S. Das et al., Race and Gender Differences in C-Reactive Protein Levels, Journal of the American College of Cardiology, vol.46, issue.3, pp.464-469, 2005.
DOI : 10.1016/j.jacc.2005.04.051

I. Ockene, C. Matthews, N. Rifai, P. Ridker, G. Reed et al., Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults, Clin Chem, issue.3, pp.47444-450, 2001.

R. Glynn, J. Macfadyen, and P. Ridker, Tracking of High-Sensitivity C-Reactive Protein after an Initially Elevated Concentration: The JUPITER Study, Clinical Chemistry, vol.55, issue.2, pp.305-312, 2009.
DOI : 10.1373/clinchem.2008.120642

D. Chiriboga, Y. Ma, W. Li, E. Stanek, J. Hebert et al., Seasonal and Sex Variation of High-Sensitivity C-Reactive Protein in Healthy Adults: A Longitudinal Study, Clinical Chemistry, vol.55, issue.2, pp.313-321, 2009.
DOI : 10.1373/clinchem.2008.111245

E. Jonathan, B. Derrick, L. Emma, P. Sarah, D. John et al., C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study, Lancet, issue.9764, pp.377469-476, 2011.

P. Sever, N. Poulter, C. Chang, A. Hingorani, S. Thom et al., Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial, European Heart Journal, vol.33, issue.4, pp.486-494, 2011.
DOI : 10.1093/eurheartj/ehr262